[Multidisciplinary treatment of cancer of the esophagus].
Multidisciplinary treatment is necessary for esophageal carcinoma. Radio-chemo-immunotherapy and aggressive chemotherapy with large doses of 5-FU, CDDP, ADR and VDS, were performed postoperatively from 1975. From 1975 to 1990, operations were performed on 456 patients with thoracic esophageal carcinomas. Postoperative radio-chemo-immunotherapy improved the 5-year survival rate of patients without lymph-node metastasis to 74.6% compared with 55.3% for patients not receiving any postoperative therapy. In the case of n1(+) and n2(+), the five-year survival rate of patients treated with aggressive chemotherapy (32.7%) was similar to the rate (34.8%) for patients treated with radio-chemo-immunotherapy. In cases of n3(+) and n4(+), improvement of the two-year survival rate of patients who received aggressive chemotherapy (37.0%) was noted compared with the rate of patients who received radio-chemo-immunotherapy (20.9%). However, there was no difference in five-year survival rate between the two groups. More effective multidisciplinary treatment based on randomized study will improve the therapeutic outcome.
Hoshino
A
A
Second Dept. of Surgery, Tohoku University School of Medicine.
Nishihira
T
T
Hirayama
K
K
Shineha
R
R
Mori
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000401:mortality / Q000628:therapy*; D004947:Esophagus / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D011879:Radiotherapy Dosage; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage
D004317:Doxorubicin; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil